PubMedPhytomedicine : international journal of phytotherapy and phytopharmacology2026-11-06
Activity of the natural biflavonoid hinokiflavone against multidrug-resistant CEM/ADR5000 leukemia cells and its modes of action via P-glycoprotein modulation.
Lei Xiao X, Taghizadeh Daria Shiva DS, Klauck Sabine M SM, Hai Yuanping Y et al.
Multidrug resistance (MDR), frequently associated with the overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp), is a major obstacle to successful leukemia chemotherapy. Natural products represent an important source for anticancer drug discovery. Hinokiflavone, a natural biflavonoid, has demonstrated anticancer potential, but its underlying mechanisms against multidrug-resistant leukemia are largely unknown.
We hypothesized that hinokiflavone exhibits preferential activity against P-gp-overexpressing multidrug-resistant leukemia cells through specific mechanisms associated with the multidrug-resistant phenotype.
Cytotoxicity was evaluated in parental and drug-resistant cell models, and the contribution of ABCB1/P-gp to the collateral sensitivity of CEM/ADR5000 cells was investigated by siRNA-mediated ABCB1 knockdown. Molecular docking was performed to predict potential interactions with both P-gp and breast cancer resistance protein (BCRP). mRNA-based transcriptomic expression profiling, Western blot analysis, pathway analyses, and siRNA-mediated TXNIP knockdown were used to investigate signaling alterations. Intracellular ROS generation, mitochondrial membrane potential, P-gp-associated drug transport, ATP levels, cell cycle distribution, DNA damage, and apoptosis were further investigated. In addition, a zebrafish xenograft model was used to evaluate preliminary in vivo antitumor activity.
Hinokiflavone exhibited collateral sensitivity toward P-gp-overexpressing CEM/ADR5000 leukemia cells, and ABCB1 knockdown markedly reduced this sensitivity. Moreover, hinokiflavone significantly restored doxorubicin sensitivity in multidrug-resistant CEM/ADR5000 cells, reducing the IC₅₀ of doxorubicin by 3.17-fold, comparable to the P-glycoprotein inhibitor verapamil. Molecular docking predicted interactions with both P-gp and BCRP. Transcriptomic and protein analyses revealed alterations in several signaling pathways (activated WNT/β-catenin signaling, increased TXNIP and PTEN expression, and reduced PI3K/AKT/mTOR signaling). TXNIP knockdown attenuated the effects of hinokiflavone on PI3K/AKT/mTOR signaling and reduced the cytotoxic response. Hinokiflavone treatment was also associated with ROS accumulation, mitochondrial membrane depolarization, altered P-gp-associated drug transport, ATP depletion, G2/M-related cell-cycle alterations, DNA damage, and apoptosis. Hinokiflavone additionally exhibited preliminary antitumor activity in an SK-N-DZ zebrafish xenograft model.
Hinokiflavone exhibits collateral sensitivity in P-gp-overexpressing CEM/ADR5000 leukemia cells, with ABCB1/P-glycoprotein contributing substantially to this phenotype. Its activity is associated with oxidative stress, energy metabolism, P-gp-associated drug transport, and multiple survival signaling pathways. These findings highlight hinokiflavone's potential for targeting multidrug-resistant leukemia.